Kiniksa Pharmaceuticals Files 8-K on Operations
Ticker: KNSA · Form: 8-K · Filed: 2024-10-29T00:00:00.000Z
Sentiment: neutral
Topics: reporting, financials
TL;DR
Kiniksa dropped an 8-K on Oct 29th - check it for financial updates.
AI Summary
Kiniksa Pharmaceuticals International, plc filed an 8-K on October 29, 2024, to report on its results of operations and financial condition, and to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies a formal update from Kiniksa Pharmaceuticals regarding its financial performance and operational status, which is crucial for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting event without immediate disclosed negative or positive financial impacts.
Key Players & Entities
- Kiniksa Pharmaceuticals International, plc (company) — Registrant
- October 29, 2024 (date) — Date of earliest event reported
- 23 Old Bond Street, Floor 3 London , WIS 4PZ England , United Kingdom (address) — Business and Mail Address
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not contain the specific details of these results or updates.
When was this 8-K filing submitted?
The filing was submitted on October 29, 2024.
What is the primary purpose of this 8-K filing for Kiniksa Pharmaceuticals International, plc?
The primary purpose is to report on the company's results of operations and financial condition, and to file financial statements and exhibits.
What is Kiniksa Pharmaceuticals International, plc's principal business address?
The company's principal business address is 23 Old Bond Street, Floor 3, London, WIS 4PZ, England, United Kingdom.
What is the Commission File Number for Kiniksa Pharmaceuticals International, plc?
The Commission File Number for Kiniksa Pharmaceuticals International, plc is 001-730430.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-10-29 07:31:21
Key Financial Figures
- $0.000273235 — h registered Class A Ordinary Shares $0.000273235 nominal value KNSA The Nasdaq Stock
Filing Documents
- tm2426983d1_8k.htm (8-K) — 24KB
- tm2426983d1_ex99-1.htm (EX-99.1) — 65KB
- tm2426983d1_ex99-1img01.jpg (GRAPHIC) — 5KB
- 0001104659-24-112034.txt ( ) — 275KB
- knsa-20241029.xsd (EX-101.SCH) — 3KB
- knsa-20241029_lab.xml (EX-101.LAB) — 33KB
- knsa-20241029_pre.xml (EX-101.PRE) — 22KB
- tm2426983d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial
Item 2.02. Results of Operations and Financial Condition On October 29, 2024, Kiniksa Pharmaceuticals International, plc issued a press release announcing financial results for the quarter ended September 30, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Q3 Earnings Press Release issued by Kiniksa Pharmaceuticals International, plc, dated October 29, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC Date: October 29, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary